More recently, Mahecha and colleagues established a mPDX model from a metastatic HER2+ gastric cancer patient and tested ado-trastuzumab emtansine as an alternative therapy for the patient, who responded to treatment before relapsing 6 months later [97]. The gene discussed is ERBB2; the disease is gastric cancer.